Clinical trials: Dry Eye Syndrome
Dry Eye Syndromes
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)
The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.
- Trial name
- NCT00548301
- Testing
- cyclosporine
- Where
- United States
- Sponsor
- Sirion Therapeutics, Inc.
Dry Eye Syndrome
Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome
This is a controlled study to determine the effectiveness and safety of KL7016 in the treatment of adult patients with dry eye syndrome (DES).
- Trial name
- NCT02092207
- Testing
- KL7016 900mg, KL7016 600mg
- Where
- 9 sites in South Korea
- Volunteers
- 147 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Dry Eye Disease
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease
- Trial name
- NCT05629364
- Testing
- KIO-101
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Dry Eye Syndromes
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
This study is a randomized, double-blind, placebo-controlled phase 1 clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of GLH8NDE after single and multiple ocular administrations in healthy…
- Trial name
- NCT04104997
- Testing
- 5% GLH8NDE
- Where
- South Korea
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Dry Eye
Tobramycin Tear Concentrations
To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.
- Trial name
- NCT00695435
- Testing
- TOBRADEX Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension, TOBREX Ophthalmic Solution
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Primary Sjogren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
- Trial name
- UPSTREAM SjD (NCT07404865)
- Testing
- Telitacicept
- Where
- 49 sites in United States, Georgia
- Volunteers
- 250 people
- Sponsor
- Vor Biopharma
Xerostomia, Hyposalivation
A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study
The purpose of this study is to evaluate the clinical efficacy, safety and acceptability of our new oral salivary equivalent in the relief of signs and symptoms related to mouth dryness as compared to two distinct moisturizing…
- Conditions
- Xerostomia, Hyposalivation, Head and Neck Cancer, Sjögren Syndrome
- Trial name
- NIAGARA (NCT02049112)
- Testing
- Salivary equivalent, Aequasyal, Biotene
- Where
- France
- Volunteers
- 210 people
- Sponsor
- Unither Pharmaceuticals, France
Dry Eye
Phase III Study of OT202 in Treating Moderate to Severe Dry Eye
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial, enrolling 842 subjects with moderate to severe dry eye, who will be randomized at a 1:1 ratio to receive either 1% OT202 ophthalmic…
- Trial name
- NCT07740564
- Testing
- OT202 conc 1%
- Where
- 49 sites in China
- Volunteers
- 842 people
- Sponsor
- Ocumension Therapeutics (Suzhou) Co., Ltd
Dry Eye Syndrome
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and along with ocular surface inflammation and damage leads to inadequate tear production and eye lubrication.
- Trial name
- NCT05878067
- Testing
- ABBV-444
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- AbbVie
Dry Eye
Phase 1 Study for Safety and Tolerability of HL036
To evaluate the safety, local tolerability and pharmacokinetic characteristics after administration of eye-drop HL036 in healthy Korean male volunteers
- Trial name
- NCT02717208
- Testing
- HL036, Vehicle
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Dry Eye
Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects
The purpose of this study is to evaluate the efficacy and safety of Systane® Gel Drops in dry eye subjects following 90 days of QID (4 times/day) dosing.
- Trial name
- NCT02380248
- Testing
- Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops
- Where
- India
- Volunteers
- 207 people
- Sponsor
- Alcon Research
Dry Eye Syndrome
In Vivo Measurement of Corneal Epithelial Changes in Dry Eye Patients
The purpose of this study is to measure corneal epithelial changes in dry eye subjects using a novel lubricant eye gel.
- Trial name
- NCT01483989
- Testing
- SYSTANE® Gel Drop lubricant eye gel
- Volunteers
- 19 people
- Sponsor
- Alcon Research
Dry Eye Disease
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
The objective of this study is to compare the safety and efficacy of OK-101 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05759208
- Testing
- OK-101
- Where
- 6 sites in United States
- Volunteers
- 240 people
- Sponsor
- Okyo Pharma Ltd
Dry Eye Syndrome
Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%
The purpose of this study is to evaluate the safety and efficacy of FID 112903 given as an immediate treatment replacement in dry eye subjects that discontinue at least 6 months use of RESTASIS.
- Trial name
- NCT01198782
- Testing
- FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)
- Volunteers
- 48 people
- Sponsor
- Alcon Research